H.C. Wainwright Reiterates Buy Rating on Microbot Medical (MBOT)

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $12.00 price target on Microbot Medical (NASDAQ: MBOT).

The analyst commented: "Last week, Microbot Medical reported over 100% growth in revenue and new customers for 2Q26 compared to 1Q26, following the commencement of full market release of the LIBERTY System on April 13, 2026. Notably, health systems in several key markets adopted the system during 2Q26, including leading health systems in Massachusetts, North Carolina, Michigan, and Pennsylvania. In addition, the company entered into an agreement with Lovell Government Services Inc. to serve federal healthcare systems. It is noteworthy that health systems that had adopted the LIBERTY System during the limited market release have increased their procedure volume in 2Q26, which should contribute to the company’s topline sales in 2H26, in our view. Microbot’s sales footprint has increased from four to eight sales territories during 2Q26 and is on track to reach 12 territories across the U.S. by the end of 2026. Outside the U.S., the company received marketing clearance from the Israeli Ministry of Health's AMAR Division. To meet current and future demand, Microbot has entered into an agreement to establish a second manufacturing site. In our view, these are encouraging signs that LIBERTY is well received by various health systems and this bodes well for the future market prospects. Looking forward to further updates in the coming months, we reiterate our Buy rating and $12 PT."

For an analyst ratings summary and ratings history on Microbot Medical click here. For more ratings news on Microbot Medical click here.

Shares of Microbot Medical closed at $1.88 yesterday.

You May Also Be Interested In

• Susquehanna Downgrades Canadian National Railway (CNI) to Neutral
• Virtu Financial posts Q2 2026 preliminary results, seeks $400M loan
• Sibyane Stillwater (SBSW) PT Lowered to $12 at BMO Capital